CLINICAL CRITERIA

临床标准

基本信息

批准号：
7264458
负责人：
BRUCE D MILLER
金额：
$ 28.53万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-01 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7264458
关键词：
Agrammatism Alzheimer&apos s Disease Amyotrophic Lateral Sclerosis Anomia Anterior Area Atrophic Basal Ganglia Behavior Behavioral Brain Stem Clinical Clinical Trials Cognitive Comprehension Data Data Analyses Deception Dementia Diagnosis Diagnostic Differential Diagnosis Disease Disinhibition Dystonia Early Diagnosis Electromyography Emotional Empathy Eye Movements Failure Focal Dystonias Frequencies Frontotemporal Dementia Frontotemporal Lobar Degenerations Genetic Genomics Goals Gold Hippocampus (Brain)Image Impairment Inferior Informal Social Control Insula of Reil Interpersonal Relations Lead Left Life Link Magnetic Resonance Imaging Measures Memory impairment Mind Molecular Motor Muscle Rigidity Neurologic Examination Neuropsychological Tests Paralysed Parietal Parkinsonian Disorders Pathology Patients Personality Phenotype Pittsburgh Compound-B Population Principal Investigator Progressive Supranuclear Palsy Proteomics Questionnaires Rate Receptive aphasia Regulation Relative (related person)Reporting Research Saccades Score Semantic Dementias Semantic memory Semantics Signal Transduction Speech Standards of Weights and Measures Syndrome Testing Ubiquitin Work amyloid imaging base cerebral atrophy concept corticobasal degeneration diagnostic accuracy executive function falls follow-up improved in vivo neuropathology novel novel diagnostics oculomotor programs showing emotion social tau Proteins theories tool white matter

项目摘要

The project's goal is to refine antemortem diagnosis of frontotemporallobar degeneration (FTLD) and related disorders by distinguishing them from Alzheimer's disease (AD), by improving early diagnosis and by differentiating patients with ubiquitin inclusions from those with tau inclusions. By the end of year 10 of the PPG this project will have obtained novel assessment on 107 AD, 131 FTD, 67 SD, 56 PNFA, 43 CBD, 30 PSP, 59 ALS, and 89 controls. Neuropathology will be completed in 37 AD, 64 FTD, 25 SD, 23 PNFA, 23 CBD, 23 PSP and 27 ALS patients. By exploring clinical pathological correlates in these populations the project will accomplish the following aims: 1. Refine diagnostic approaches to FTD, PNFA, SD, CBD, and PSP in order to improve separation of these patient groups during life from patients with AD. This aim will be facilitated by the use of amyloid imaging with the Pittsburgh-compound-B (PIB). Also, genomics and proteomics will be preliminarily explored as tools for differential diagnosis of FTD, PNFA, SD, CBD and PSP from each other, and from AD. 2. Explore the earliest changes in FTD patients with a clinical dementia rating (CDR) score of 0.5, and ALS patients (many will have early FTD). This aim will be tested using novel paradigms that capture social, emotional and imaging domains through the Clinical and Administrative Core and in projects 2, 3 and 4. Also, genomics and proteomics will be explored as potential markers of early FTD or FTD-ALS. 3. Identify syndromes that best predict FTLD-T vs. FTLD-U as defined at pathology. The aim will be performed by analyzing data collected through the Clinical and Administrative Core and projects 2 and 3. Also, genomic and proteomic profiles will be explored in these populations.

该项目的目的是完善额叶甲虫变性（FTLD）和通过将它们与阿尔茨海默氏病（AD）区分开，通过改善早期诊断和通过将泛素夹杂物与TAU夹杂物患者区分开来。到第10年底 ppg这个项目将在107 AD，131 FTD，67 SD，56 PNFA，43 CBD，30中获得新的评估。 PSP，59 ALS和89个对照。神经病理学将在公元37年，64 FTD，25 SD，23 PNFA，23中完成 CBD，23个PSP和27名ALS患者。通过探索这些人群中的临床病理关系项目将实现以下目的：1。改进FTD，PNFA，SD，CBD和 PSP是为了在生活中与AD患者的生活中的分离改善这些患者群体的分离。这个目标将是通过与匹兹堡 - 混合-B（PIB）使用淀粉样蛋白成像的促进。另外，基因组学和蛋白质组学将作为FTD，PNFA，SD，CBD和PSP的鉴别诊断的工具进行初步探讨彼此和广告。 2。探索临床痴呆评级的FTD患者的最早变化（CDR）评分为0.5，ALS患者（许多将具有早期FTD）。这个目标将使用小说进行测试通过临床和行政核心捕获社交，情感和成像领域的范例在项目2、3和4中。此外，基因组学和蛋白质组学也将作为早期的潜在标志 FTD或FTD-ALS。 3。确定最能预测FTLD-T与FTLD-U的综合征，如病理所定义。这 AIM将通过分析通过临床和行政核心收集的数据来执行AIM 2 和3。此外，这些人群将探索基因组和蛋白质组学特征。